Anders Sönnerborg to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications Anders Sönnerborg has written about Antiretroviral Therapy, Highly Active.
Connection Strength
0.898
-
Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients. PLoS One. 2017; 12(7):e0180140.
Score: 0.452
-
Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. J Med Virol. 2009 Jan; 81(1):1-8.
Score: 0.250
-
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. PLoS One. 2017; 12(6):e0178942.
Score: 0.112
-
Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers. Sci Rep. 2017 07 24; 7(1):6269.
Score: 0.028
-
Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy. Sci Rep. 2017 04 06; 7(1):666.
Score: 0.028
-
Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci Rep. 2017 01 13; 7:40354.
Score: 0.027